- Home
- SAVA vs CNTX Comparison
SAVA vs CNTX Comparison
Compare SAVA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CNTX
- Stock Information
- Founded
- SAVA 1998
- CNTX 2015
- Country
- SAVA United States
- CNTX United States
- Employees
- SAVA N/A
- CNTX N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- CNTX Health Care
- Exchange
- SAVA Nasdaq
- CNTX Nasdaq
- Market Cap
- SAVA 70.5M
- CNTX 78.0M
- IPO Year
- SAVA N/A
- CNTX 2021
- Fundamental
- Price
- SAVA $2.35
- CNTX $0.84
- Analyst Decision
- SAVA Buy
- CNTX Strong Buy
- Analyst Count
- SAVA 2
- CNTX 5
- Target Price
- SAVA $54.50
- CNTX $5.50
- AVG Volume (30 Days)
- SAVA 1.2M
- CNTX 197.0K
- Earning Date
- SAVA 08-07-2025
- CNTX 08-06-2025
- Dividend Yield
- SAVA N/A
- CNTX N/A
- EPS Growth
- SAVA N/A
- CNTX N/A
- EPS
- SAVA N/A
- CNTX N/A
- Revenue
- SAVA N/A
- CNTX N/A
- Revenue This Year
- SAVA N/A
- CNTX N/A
- Revenue Next Year
- SAVA N/A
- CNTX N/A
- P/E Ratio
- SAVA N/A
- CNTX N/A
- Revenue Growth
- SAVA N/A
- CNTX N/A
- 52 Week Low
- SAVA $1.15
- CNTX $0.49
- 52 Week High
- SAVA $42.20
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- SAVA 56.89
- CNTX 64.84
- Support Level
- SAVA $2.11
- CNTX $0.82
- Resistance Level
- SAVA $2.72
- CNTX $0.87
- Average True Range (ATR)
- SAVA 0.16
- CNTX 0.07
- MACD
- SAVA 0.04
- CNTX 0.01
- Stochastic Oscillator
- SAVA 52.56
- CNTX 58.27
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.